Small-dose combined medicine composition for treating intractable hypertension

A stubborn, low-dose technology, applied in drug combinations, active ingredients of heterocyclic compounds, blood diseases, etc., can solve the problems of small toxic and side effects, antihypertensive drug side effects, etc., to achieve small side effects, significant antihypertensive effect, effective lasting effect

Inactive Publication Date: 2021-12-03
葛荣专
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Hypertension is a multifactorial disease that generally requires long-term medication and lifelong monitoring. However, antihypertensive drugs have varying degrees of toxic and side effects, so it is necessary to develop an effective drug for resistant hypertension with less toxic and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 15mg angiotensin converting enzyme inhibitors, calcium antagonists, betablockers 8 mg, 15 mg diuretic , a receptor blockers 15 mg, nitroglycerin 0.2 mg, Ginkgo biloba 2 mg, Salvia 100 mg, estazolam 0.3 mg, diazepam 1 mg, isosorbide dinitrate 2 mg, 5 mg aspirin , aliphatic isoamyl nitrite 0.5 mg, atorvastatin calcium 4 mg, and amlodipine besylate 1mg clopidogrel hydrogen sulfate 13 mg.

[0020] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is metoprolol. The diuretic is hydrochlorothiazide.

[0021] After the above components were uniformly mixed and formed into tablets.

Embodiment 2

[0023] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 10mg angiotensin converting enzyme inhibitors, calcium antagonists, betablockers 10 mg, 10 mg diuretic , a receptor blockers 25 mg, nitroglycerin 0.1 mg, Ginkgo biloba 4mg, Salvia 80mg, estazolam 0.5 mg, diazepam 3mg, isosorbide dinitrate 1 mg, aspirin 3 mg, nitrite isoamyl fat 0.2 mg, atorvastatin calcium 8 mg, 3 mg of amlodipine besylate and clopidogrel bisulfate 8 mg.

[0024] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is atenolol. The diuretic is hydrochlorothiazide.

[0025] After the above components were uniformly mixed and formed into tablets.

Embodiment 3

[0027] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 25mg angiotensin converting enzyme inhibitor, calcium antagonist of 5 mg, 25 mg diuretic , a receptor blockers 10mg, nitroglycerin 0.3 mg, Ginkgo biloba 1 mg, Salvia 130mg, estazolam 0.1 mg, diazepam 0.5 mg, isosorbide dinitrate 3 mg, aspirin 8 mg, ethylene isoamyl nitrate lipid 0.8mg, atorvastatin calcium 2 mg, 0.5mg amlodipine besylate and clopidogrel bisulfate 20mg.

[0028] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is metoprolol. The diuretic is hydrochlorothiazide.

[0029] After the above components were uniformly mixed and formed into tablets.

[0030] The pharmaceutical compositions of the present invention can be better blood pressure, heart and stabilize cardiovascular benefit, while for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a small-dose combined medicine composition for treating intractable hypertension. The composition comprises the following components in parts by weight: 10-25 parts of an angiotensin transenzyme inhibitor, 5-10 parts of a calcium ion orange resistant agent, 10-25 parts of a diuretic, 10-25 parts of an a receptor blocker, 0.1-0.3 part of nitroglycerin, 1-4 parts of folium ginkgo, 80-130 parts of radix salviae miltiorrhizae, 0.1-0.5 part of estazolam, 0.5-3 parts of diazepam, 1-3 parts of isosorbide dinitrate, 3-8 parts of aspirin, 0.2-0.8 part of isoamyl nitrite, 2-8 parts of atorvastatin calcium, 0.5-3 parts of amlodipine besylate and 8-20 parts of clopidogrel hydrogen sulfate. The medicine composition has small toxic and side effects and can effectively treat intractable hypertension.

Description

Technical field [0001] The present invention belongs to the field of pharmaceutical chemistry, specifically relates to a pharmaceutical composition with a small-dose combination therapy resistant hypertension. Background technique [0002] Hypertension refers to the systemic arterial blood pressure (systolic and / or diastolic blood pressure) increases as the main feature (≥140 mm Hg systolic blood pressure, diastolic blood pressure ≥90 mm Hg), may be associated with heart, brain, kidney and other organ function or clinical syndrome of organic damage. Hypertension is the most common chronic disease, cardiovascular disease is the most important risk factor. With normal blood pressure fluctuations in external environmental changes within a certain range. In the general population, blood pressure gradually increased with age, systolic blood pressure is more obvious, but the 50-year-old downward trend in diastolic blood pressure, pulse pressure also will increase. [0003] Hypertensi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/138A61K31/165A61K31/21A61K31/34A61K31/40A61K31/401A61K31/4365A61K31/4422A61K31/549A61K31/5513A61K31/5517A61K31/60A61K36/16A61K36/537A61P3/10A61P7/02A61P9/10A61P9/12A61P13/12
CPCA61K45/06A61K31/21A61K36/16A61K36/537A61K31/5513A61K31/60A61K31/40A61K31/4422A61K31/4365A61K31/34A61K31/5517A61K31/401A61K31/138A61K31/165A61K31/549A61P9/12A61P9/10A61P3/10A61P13/12A61P7/02A61K2300/00
Inventor 葛荣专葛红明
Owner 葛荣专
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap